News | May 04, 2024
Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
Topiramate is the generic version of Supernus Pharmaceuticals’ Trokendi XR
The company has reported total income of Rs. 1052.79 crores during the period ended June 30, 2023
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
India business is growing as per projections; whereas US business will bounce back soon.
It posted net profit of Rs.147.76 crores for the period ended June 30, 2020.
The companyreported total income of Rs.2915.67 crores during the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)